R&D The race for obesity drug assets heats up The existing treatments for weight loss have drawn interest from across the industry, as their efficacy and sales potential become evident.
Patients Why medical weight loss is more complicated than GLP-1s A few weeks ago on the pharmaphorum podcast, we discussed the new GLP-1 weight loss drugs and their shake-up effect on the medical weight loss industry.
R&D GLP-1 weight loss drugs: An overview and update GLP-1 agonists like Ozempic, Wegovy, and Mounjaro are dramatically changing the field of medically-assisted weight loss.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.